Open AccessIncreased IL-33 and IL-17 in Colorectal Carcinoma Patients with Severe Disease
Author(s) -
Veljko Marić,
Milan Jovanović,
Nataša Zdravković,
Marina Jovanović,
Nevena Gajović,
Milena Jurišević,
Marina Jovanović,
Ivan Jovanović
Publication year - 2020
Publication title -
serbian journal of experimental and clinical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.131
H-Index - 8
eISSN - 2335-075X
pISSN - 1820-8665
DOI - 10.2478/sjecr-2018-0034
Subject(s) - medicine , colorectal cancer , feces , metastasis , gastroenterology , lung , carcinoma , pathology , cancer , paleontology , biology
Colorectal cancer (CRC) represents one of the most common cancers. It is frequently diagnosed at advanced stages, indicating on need for new diagnostic markers. The aim of this study was to determine systemic and fecal values of IL-17 and IL-33 in patients with CRC and the relationship with clinicopathological aspects of disease. The blood samples and feces liquid fraction of 50 patients with CRC were analyzed. Serum and fecal levels of IL-33 and IL-17 were measured using sensitive enzyme-linked immunosorbent assay (ELISA) kits. Fecal levels of Il-33 and IL-17 were increased in CRC patients with poor tumor tissue differentiation. Serum IL-33 and fecal IL-17 were increased in patients with presence of lung/liver metastasis or peritoneal carcinomatosis, respectively, while enhanced fecal IL-33 was detected only in patients with peritoneal carcinomatosis. Positive correlation between IL-33 and IL-17 values in sera and feces, respectively was also observed. We believe that increased local values of IL-33 and IL-17, reflected trough higher fecal concentration, in CRC patients with poor tumor tissue differentiation and with presence of lung/liver metastasis or peritoneal carcinomatosis may be considered as a sign of the tumor’s malignant progression and, consequently, of a poor prognosis for patients.